Found 101 with Last Name = 'byrne' and Initial = 'n' 
Affinity DataIC50: 3nMAssay Description:Inhibition of human CAMKK2 using CAMKKtide as substrate assessed as residual activity by [gamma-33P]-ATP assay relative to controlMore data for this Ligand-Target Pair
3D Structure (crystal)
Affinity DataIC50: 3nMAssay Description:Inhibition of NanoLuc-fused CAMKK2 (unknown origin) expressed in HEK293 cells after 24 hrs by NanoBRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of NanoLuc-fused CAMKK2 (unknown origin) expressed in HEK293 cells after 24 hrs by NanoBRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Inhibition of human CAMKK2 using CAMKKtide as substrate assessed as residual activity by [gamma-33P]-ATP assay relative to controlMore data for this Ligand-Target Pair
Affinity DataIC50: 8.10nMAssay Description:Inhibition of NanoLuc-fused CAMKK2 (unknown origin) expressed in HEK293 cells after 24 hrs by NanoBRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 12nMAssay Description:Inhibition of human CAMKK2 using CAMKKtide as substrate assessed as residual activity by [gamma-33P]-ATP assay relative to controlMore data for this Ligand-Target Pair
Affinity DataIC50: 13nMAssay Description:Inhibition of human CAMKK2 using CAMKKtide as substrate assessed as residual activity by [gamma-33P]-ATP assay relative to controlMore data for this Ligand-Target Pair
Affinity DataIC50: 21nMAssay Description:Inhibition of human CAMKK2 using CAMKKtide as substrate assessed as residual activity by [gamma-33P]-ATP assay relative to controlMore data for this Ligand-Target Pair
Affinity DataIC50: 21nMAssay Description:Inhibition of human CAMKK2 using CAMKKtide as substrate assessed as residual activity by [gamma-33P]-ATP assay relative to controlMore data for this Ligand-Target Pair
Affinity DataIC50: 23nMAssay Description:Inhibition of human CAMKK2 using CAMKKtide as substrate assessed as residual activity by [gamma-33P]-ATP assay relative to controlMore data for this Ligand-Target Pair
Affinity DataIC50: 24nMAssay Description:Inhibition of human CAMKK2 using CAMKKtide as substrate assessed as residual activity by [gamma-33P]-ATP assay relative to controlMore data for this Ligand-Target Pair
Affinity DataIC50: 26nMAssay Description:Inhibition of human CAMKK2 using CAMKKtide as substrate assessed as residual activity by [gamma-33P]-ATP assay relative to controlMore data for this Ligand-Target Pair
Affinity DataIC50: 27nMAssay Description:Inhibition of human CAMKK1 using CAMKKtide as substrate assessed as residual activity by [gamma-33P]-ATP assay relative to controlMore data for this Ligand-Target Pair
Affinity DataIC50: 31nMAssay Description:Inhibition of human CAMKK1 using CAMKKtide as substrate assessed as residual activity by [gamma-33P]-ATP assay relative to controlMore data for this Ligand-Target Pair
Affinity DataIC50: 31nMAssay Description:Inhibition of human CAMKK2 using CAMKKtide as substrate assessed as residual activity by [gamma-33P]-ATP assay relative to controlMore data for this Ligand-Target Pair
Affinity DataIC50: 33nMAssay Description:Inhibition of human CAMKK1 using CAMKKtide as substrate assessed as residual activity by [gamma-33P]-ATP assay relative to controlMore data for this Ligand-Target Pair
Affinity DataIC50: 39nMAssay Description:Inhibition of CAMKK2 in human LNCaP C4-2 cells assessed as reduction AMPK phosphorylation at Thr172 incubated for 24 hrs by Western blot analysisMore data for this Ligand-Target Pair
Affinity DataIC50: 44nMAssay Description:Inhibition of human CAMKK2 using CAMKKtide as substrate assessed as residual activity by [gamma-33P]-ATP assay relative to controlMore data for this Ligand-Target Pair
Affinity DataIC50: 51nMAssay Description:Inhibition of human CAMKK2 using CAMKKtide as substrate assessed as residual activity by [gamma-33P]-ATP assay relative to controlMore data for this Ligand-Target Pair
Affinity DataIC50: 56nMAssay Description:Inhibition of human CAMKK2 using CAMKKtide as substrate assessed as residual activity by [gamma-33P]-ATP assay relative to controlMore data for this Ligand-Target Pair
Affinity DataIC50: 65nMAssay Description:Inhibition of human CAMKK2 using CAMKKtide as substrate assessed as residual activity by [gamma-33P]-ATP assay relative to controlMore data for this Ligand-Target Pair
Affinity DataIC50: 96nMAssay Description:Inhibition of human CAMKK2 using CAMKKtide as substrate assessed as residual activity by [gamma-33P]-ATP assay relative to controlMore data for this Ligand-Target Pair
Affinity DataIC50: 108nMAssay Description:Inhibition of human CAMKK2 using CAMKKtide as substrate assessed as residual activity by [gamma-33P]-ATP assay relative to controlMore data for this Ligand-Target Pair
Affinity DataIC50: 120nMAssay Description:Inhibition of human CAMKK2 using CAMKKtide as substrate assessed as residual activity by [gamma-33P]-ATP assay relative to controlMore data for this Ligand-Target Pair
Affinity DataIC50: 137nMAssay Description:Inhibition of human CAMKK2 using CAMKKtide as substrate assessed as residual activity by [gamma-33P]-ATP assay relative to controlMore data for this Ligand-Target Pair
Affinity DataIC50: 140nMAssay Description:Inhibition of NanoLuc-fused CAMKK2 (unknown origin) expressed in HEK293 cells after 24 hrs by NanoBRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 141nMAssay Description:Inhibition of human DAOMore data for this Ligand-Target Pair
Affinity DataIC50: 145nMAssay Description:Inhibition of human CAMKK2 using CAMKKtide as substrate assessed as residual activity by [gamma-33P]-ATP assay relative to controlMore data for this Ligand-Target Pair
Affinity DataIC50: 169nMAssay Description:Inhibition of human CAMKK2 using CAMKKtide as substrate assessed as residual activity by [gamma-33P]-ATP assay relative to controlMore data for this Ligand-Target Pair
Affinity DataIC50: 170nMAssay Description:Inhibition of NanoLuc-fused CAMKK2 (unknown origin) expressed in HEK293 cells after 24 hrs by NanoBRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 190nMAssay Description:Inhibition of NanoLuc-fused CAMKK2 (unknown origin) expressed in HEK293 cells after 24 hrs by NanoBRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 193nMAssay Description:Inhibition of human CAMKK2 using CAMKKtide as substrate assessed as residual activity by [gamma-33P]-ATP assay relative to controlMore data for this Ligand-Target Pair
Affinity DataIC50: 195nMAssay Description:Inhibition of human CAMKK1 using CAMKKtide as substrate assessed as residual activity by [gamma-33P]-ATP assay relative to controlMore data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:Inhibition of NanoLuc-fused CAMKK2 (unknown origin) expressed in HEK293 cells after 24 hrs by NanoBRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 210nMAssay Description:Inhibition of NanoLuc-fused CAMKK2 (unknown origin) expressed in HEK293 cells after 24 hrs by NanoBRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 232nMAssay Description:Inhibition of human CAMKK2 using CAMKKtide as substrate assessed as residual activity by [gamma-33P]-ATP assay relative to controlMore data for this Ligand-Target Pair
Affinity DataIC50: 238nMAssay Description:Inhibition of human DAOMore data for this Ligand-Target Pair
Affinity DataIC50: 238nMAssay Description:Inhibition of human CAMKK1 using CAMKKtide as substrate assessed as residual activity by [gamma-33P]-ATP assay relative to controlMore data for this Ligand-Target Pair
Affinity DataIC50: 239nMAssay Description:Inhibition of human CAMKK1 using CAMKKtide as substrate assessed as residual activity by [gamma-33P]-ATP assay relative to controlMore data for this Ligand-Target Pair
Affinity DataIC50: 240nMAssay Description:Inhibition of NanoLuc-fused CAMKK2 (unknown origin) expressed in HEK293 cells after 24 hrs by NanoBRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 245nMAssay Description:Inhibition of human DAOMore data for this Ligand-Target Pair
Affinity DataIC50: 269nMAssay Description:Inhibition of human DAOMore data for this Ligand-Target Pair
Affinity DataIC50: 290nMAssay Description:Inhibition of NanoLuc-fused CAMKK2 (unknown origin) expressed in HEK293 cells after 24 hrs by NanoBRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 343nMAssay Description:Inhibition of human DAOMore data for this Ligand-Target Pair
Affinity DataIC50: 384nMAssay Description:Inhibition of human CAMKK1 using CAMKKtide as substrate assessed as residual activity by [gamma-33P]-ATP assay relative to controlMore data for this Ligand-Target Pair
Affinity DataIC50: 390nMAssay Description:Inhibition of CAMKK2 in human LNCaP C4-2 cells assessed as reduction AMPK phosphorylation at Thr172 incubated for 24 hrs by Western blot analysisMore data for this Ligand-Target Pair
Affinity DataIC50: 407nMAssay Description:Inhibition of human CAMKK1 using CAMKKtide as substrate assessed as residual activity by [gamma-33P]-ATP assay relative to controlMore data for this Ligand-Target Pair
Affinity DataIC50: 470nMAssay Description:Inhibition of NanoLuc-fused CAMKK2 (unknown origin) expressed in HEK293 cells after 24 hrs by NanoBRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 507nMAssay Description:Inhibition of human DAOMore data for this Ligand-Target Pair
Affinity DataIC50: 516nMAssay Description:Inhibition of human DAOMore data for this Ligand-Target Pair
